- Home
- SVII vs CRBP Comparison
SVII vs CRBP Comparison
Compare SVII & CRBP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SVII
- CRBP
- Stock Information
- Founded
- SVII 2021
- CRBP 2009
- Country
- SVII United States
- CRBP United States
- Employees
- SVII N/A
- CRBP N/A
- Industry
- SVII Blank Checks
- CRBP Biotechnology: Pharmaceutical Preparations
- Sector
- SVII Finance
- CRBP Health Care
- Exchange
- SVII Nasdaq
- CRBP Nasdaq
- Market Cap
- SVII 112.1M
- CRBP 103.6M
- IPO Year
- SVII 2022
- CRBP N/A
- Fundamental
- Price
- SVII $11.33
- CRBP $8.18
- Analyst Decision
- SVII
- CRBP Strong Buy
- Analyst Count
- SVII 0
- CRBP 8
- Target Price
- SVII N/A
- CRBP $61.38
- AVG Volume (30 Days)
- SVII 337.0
- CRBP 296.4K
- Earning Date
- SVII 01-01-0001
- CRBP 03-11-2025
- Dividend Yield
- SVII N/A
- CRBP N/A
- EPS Growth
- SVII 13.16
- CRBP N/A
- EPS
- SVII 0.36
- CRBP N/A
- Revenue
- SVII N/A
- CRBP N/A
- Revenue This Year
- SVII N/A
- CRBP N/A
- Revenue Next Year
- SVII N/A
- CRBP N/A
- P/E Ratio
- SVII $31.42
- CRBP N/A
- Revenue Growth
- SVII N/A
- CRBP N/A
- 52 Week Low
- SVII $10.91
- CRBP $7.64
- 52 Week High
- SVII $11.70
- CRBP $61.90
- Technical
- Relative Strength Index (RSI)
- SVII 59.82
- CRBP 35.10
- Support Level
- SVII $11.20
- CRBP $7.64
- Resistance Level
- SVII $11.24
- CRBP $9.51
- Average True Range (ATR)
- SVII 0.00
- CRBP 0.84
- MACD
- SVII -0.00
- CRBP -0.05
- Stochastic Oscillator
- SVII 50.00
- CRBP 13.71
About SVII Spring Valley Acquisition Corp. II
Spring Valley Acquisition Corp II is a blank check company.
About CRBP Corbus Pharmaceuticals Holdings Inc.
Corbus Pharmaceuticals Holdings Inc is a precision oncology company with a diversified portfolio and is committed to helping people defeat serious illness by bringing scientific approaches to well-understood biological pathways. The company's development pipeline includes; CRB-701, a next-generation antibody-drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGF expressed on cancer cells, and CRB-913 a second-generation peripherally restricted CB1 receptor inverse agonist designed to treat obesity.